Cue Biopharma, Inc. (CUE) Form 8-K — Aug 14, 2026
Cue Biopharma reported Q2 2026 revenue of $7.9 million, up from $3.0 million a year ago, driven by a preclinical milestone under its Boehringer Ingelheim collaboration. Net loss widened to $153.1 million from $8.5 million, with EPS of -$24.14 versus -$2.67, as the quarter absorbed one-time charges tied to the Ascendant CUE-221 license agreement.
Key figures
- Revenue
- 7900000
- Revenue Yoy
- $7.9M vs $3.0M in Q2 2025 (~163% increase, driven by Boehringer Ingelheim preclinical milestone)
- Cash Position
- 17400000
- Gross Proceeds
- 50000000
- Shares Outstanding
- 6340844
- Total assets
- 30707000
- Q2 2025 revenue
- 3000000
- Q2 2025 net loss
- 8500000
- Six month revenue
- 13563000
- Total liabilities
- 28397000
- Ga expense q2 2025
- 3700000
- Ga expense q2 2026
- 46600000
- Rd expense q2 2025
- 7900000
- Rd expense q2 2026
- 49000000
- Six month net loss
- 158245000
- Non cash stock comp
- 19700000
- Stockholders equity
- 2310000
- Q2 2025 weighted avg shares
- 3181980
- Non cash loss ascendant license
- 63100000
- Integration transaction costs ga
- 23000000
- One time cash payments ascendant
- 20000000
- Warrant fair value expense ascendant
- 20000000
- Fair value gain financial instruments
- 24487000
- Loss on liability classified warrants
- 90011000
Price after filing
1 day: 0.0%7 days: -29.9%30 days: -16.0%
Close on the filing date to close N calendar days later (from $34.20). Historical, not a forecast.
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.